Streetbeat News

Regulatory

BLK

BTCUSD

Steven McClurg, CIO at Valkyrie, is optimistic that the U.S. Securities and Exchange Commission (SEC) might approve a spot Bitcoin (BTC) ETF soon. Valkyrie oversees two ETFs with assets totaling $51.1 million. Investment giants such as BlackRock Inc. (BLK), Fidelity Investments, and Grayscale Investments are among those awaiting the SEC's approval to transition from Bitcoin futures to holding actual Bitcoin in their ETFs. McClurg estimates around $10 billion in demand shortly after the launch of such an ETF.

Portfolio Pulse from Murtuza Merchant

November 03, 2023 | 4:50 pm

CVRX

CVRx Inc announced that the Centers for Medicare and Medicaid Services (CMS) has reassigned the Barostim implant procedure for procedures performed in the outpatient setting as part of the 2024 Medicare Hospital Outpatient Prospective Payment System (OPPS) final rule. The new payment takes effect January 1, 2024, and carries an average payment of $45,000, up from $29,000 in 2023. CVRx shares are up 25.50% at $17.09 on the last check Friday.

Portfolio Pulse from Vandana Singh

November 03, 2023 | 4:46 pm

BBU

Brookfield Business Partners reported Q3 financial results and announced it received regulatory approval for the sale of Westinghouse. This news led to a rise in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:32 pm

MDNA

Medicenna Therapeutics Corp. (TSX:MDNA) presented new preclinical data on its T-MASK platform and MDNA113, a first-in-class IL-13R⍺2 targeted therapy, at the 38th Annual Meeting of the Society for Immunotherapy of Cancer. The data shows the platform's ability to enhance tumor specific accumulation, increase anti-tumor activity, and improve the safety profile of immune modulators. MDNA113 is designed to deliver bispecific IL-2-antiPD1 Superkine to cancers that express the tumor associate antigen, IL-13R⍺2, which is linked to aggressive cancers affecting over 2 million patients annually.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:13 pm

INAB

IN8bio, Inc. (NASDAQ:INAB) presented new positive preclinical data from its induced pluripotent stem cell (iPSC) gamma-delta T cell platform at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting. The data represents a significant advance in the development of the INB-500 iPSC program towards the development of allogeneic gamma-delta T cell therapies. The company's proprietary process can be scaled for full GMP manufacturing, and the iPSC-derived gamma-delta T cells have shown strong cancer-killing abilities against various solid and liquid cancers.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:12 pm

XLO

Xilio Therapeutics announced initial monotherapy safety and anti-tumor activity data for XTX202, a tumor-activated, engineered, Beta-Gamma IL-2, in late line patients with advanced solid tumors. The treatment showed a 50% disease control rate at higher doses and 31% across all dose levels. Adverse events were primarily Grade 1-2 at doses up to 4 mg/kg. Two patients have been on the treatment for over a year, indicating good tolerance. Xilio plans to evaluate XTX202 in a Phase 2 trial in patients with advanced melanoma and renal cell carcinoma.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:12 pm

SGEN

Seagen Inc. (NASDAQ:SGEN) presented initial Phase 2 data for ADCETRIS in combination with immunotherapy pembrolizumab in metastatic non-small cell lung cancer and metastatic cutaneous melanoma at the Society for Immunotherapy of Cancer Annual Meeting. The company also shared preclinical data for a novel antibody-drug conjugate SGN-35T. The combination of ADCETRIS and a PD-1 inhibitor showed promising results, supporting continued research. Seagen plans to begin enrolling patients in a phase 1 clinical trial for SGN-35T soon.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:12 pm

TLSI

TriSalus Life Sciences (NASDAQ:TLSI) has presented positive safety and feasibility data from a Phase 1 trial of its investigational class C toll-like receptor-9 (TLR9) agonist, SD-101, for pancreatic adenocarcinoma at the Society of Immunotherapy for Cancer (SITC) 2023 Annual Meeting. The data from the PERIO-03 clinical trial indicates that the Pressure-Enabled Drug Delivery (PEDD) method resulted in modulation of the tumor microenvironment. The trial revealed no serious grade 3/4 adverse events related to treatment in three patients who received SD-101 via retrograde venous infusion PEDD at the lowest dose level.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:11 pm

XAIR

Beyond Cancer, an affiliate of Beyond Air, Inc. (NASDAQ:XAIR), presented first-in-human clinical data for ultra-high concentration nitric oxide (UNO) therapy in solid tumors at the Society for Immunotherapy of Cancer 2023 Annual Meeting. The Phase 1 study showed promising safety profile and clear evidence of immune system activation. Additional Phase 1 data for UNO is expected in 2024.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:10 pm

MOLN

Molecular Partners AG (NASDAQ:MOLN) has presented positive data from its ongoing Phase 1 trial of MP0317 monotherapy in patients with advanced solid tumors at the 2023 SITC Annual Meeting. The data shows that MP0317 continues to demonstrate tumor-localized CD40 activation, leading to elevated immune activity in the tumor microenvironment. The monotherapy also shows a favorable safety profile up to the highest planned doses. The company expects to share final results of this study in 2024.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:09 pm